These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 9208357)

  • 1. Pharmacokinetics of pirmenol enantiomers and pharmacodynamics of pirmenol racemate in patients with premature ventricular contractions.
    Janiczek N; Smith DE; Chang T; Sedman AJ; Stringer KA
    J Clin Pharmacol; 1997 Jun; 37(6):502-13. PubMed ID: 9208357
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics and pharmacodynamics of pirmenol enantiomers in coronary artery ligated dogs.
    Janiczek N; Smith DE; Chang T; Ventura A; Mertz TE
    J Pharm Sci; 1997 Apr; 86(4):443-9. PubMed ID: 9109046
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacodynamics and pharmacokinetics of oral pirmenol.
    Ellenbogen KA; Roark SF; Sintetos AL; Smith MS; McCarthy EA; Smith WM; Kates RE; Pritchett EL
    Clin Pharmacol Ther; 1987 Oct; 42(4):405-10. PubMed ID: 3665339
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Stereoselective high-performance liquid chromatographic assay for pirmenol enantiomers in dog plasma.
    Janiczek N; Bockbrader HN; Chang T; Amidon GL; Smith DE
    J Chromatogr; 1991 Nov; 571(1-2):179-87. PubMed ID: 1810946
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and pharmacokinetics of oral pirmenol, a new antiarrhythmic drug.
    Garg DC; Jallad NS; Singh S; Ng KF; Weidler DJ
    J Clin Pharmacol; 1988 Sep; 28(9):812-7. PubMed ID: 2466056
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The relation of the kinetics of pirmenol to its antiarrhythmic efficacy.
    Johnson BF; Haffajee CI; Woodman T; Sloan KL
    J Clin Pharmacol; 1988 May; 28(5):401-5. PubMed ID: 3392237
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Enhanced pirmenol elimination by rifampin.
    Stringer KA; Cetnarowski AB; Goldfarb A; Lebsack ME; Chang T; Sedman AJ
    J Clin Pharmacol; 1988 Dec; 28(12):1094-7. PubMed ID: 3243925
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical pharmacology and pharmacokinetics of pirmenol.
    Reiter MJ
    Angiology; 1988 Mar; 39(3 Pt 2):293-8. PubMed ID: 3281518
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics of pirmenol in young and elderly subjects.
    Ferry DG; Campbell AJ; Bland R; Beasley M; Gazeley L; Edwards IR
    Eur J Clin Pharmacol; 1992; 43(4):437-9. PubMed ID: 1451728
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pirmenol, a new antiarrhythmic agent: initial study of efficacy, safety and pharmacokinetics.
    Hammill SC; Shand DG; Routledge PA; Hindman MC; Baker JT; Pritchett EL
    Circulation; 1982 Feb; 65(2):369-75. PubMed ID: 7053896
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical effects and pharmacokinetics of a single oral dose of pirmenol hydrochloride.
    Atarashi H; Kuruma A; Ino T; Hirayama Y; Saitoh H; Hayakawa H
    J Cardiovasc Pharmacol; 1996 Apr; 27(4):556-62. PubMed ID: 8847873
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effect of pirmenol administration on the anti-coagulant activity of warfarin.
    Stringer KA; Switzer DF; Abadier R; Lebsack ME; Sedman A; Chrymko M
    J Clin Pharmacol; 1991 Jul; 31(7):607-10. PubMed ID: 1894756
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Disposition of intravenous pirmenol.
    Sanders SW; Nappi JM; Foltz RL; Lutz JR; Anderson JL
    J Clin Pharmacol; 1983; 23(2-3):113-22. PubMed ID: 6853743
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Electrophysiologic effects of pirmenol, its metabolite 2, and enantiomers, on cardiac Purkinje fibers.
    Lee JH; Rosen MR
    J Cardiovasc Pharmacol; 1993 Sep; 22(3):416-22. PubMed ID: 7504132
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preclinical and clinical pharmacokinetics of pirmenol.
    Chang T
    Am J Cardiol; 1987 Jun; 59(16):15H-19H. PubMed ID: 2438922
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Population pharmacokinetics, protein binding and antiarrhythmic effects of disopyramide enantiomers in arrhythmic patients.
    Aso R; Ohashi K; Katoh T; Ogata H
    Int J Clin Pharmacol Res; 2001; 21(3-4):137-46. PubMed ID: 12067143
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Binding profiles of class I antiarrhythmic agents to cardiac muscarinic receptors: competitive and allosteric interactions with the receptors and their pharmacological significance.
    Endou M; Gando S; Hattori Y; Kanno M
    J Pharmacol Exp Ther; 1991 Sep; 258(3):992-8. PubMed ID: 1890628
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A multicenter dose-response study of pirmenol hydrochloride in patients with ventricular premature contractions.
    Farnham DJ
    Am J Cardiol; 1987 Jun; 59(16):43H-47H. PubMed ID: 2438923
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genotoxicity assessment of pirmenol, a new antiarrhythmic drug.
    Ciaravino V; Kropko ML; Krishna G; Monteith DK; Theiss JC
    Mutat Res; 1992; 280(3):205-14. PubMed ID: 1381484
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pirmenol for control of ventricular arrhythmias: oral dose-ranging and short-term maintenance study.
    Anderson JL; Lutz JR; Nappi JM
    Am J Cardiol; 1984 Feb; 53(4):522-7. PubMed ID: 6198894
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.